[en] OBJECTIVE: Our aim was to report the recent changes in diagnosis and management of TSH-secreting pituitary adenomas. METHODS: We retrieved 43 consecutive patients with TSH-secreting pituitary tumors (23 male and 20 female) among 4400 pituitary adenomas followed between 1976 and 2001 in six Belgian and French centers. RESULTS: TSH was elevated in 18/43 and alpha subunit in 13/32 patients. In patients with intact thyroid (n=30), mean free tri-iodothyronine was 13.1 pmol/l (range 3.5-23) and mean free thyroxine was 38.4 pmol/l (range 10.2-62.7). Hyperprolactinemia and acromegaly were associated in 9/43 and 8/43 cases. The number of associated hypersecretions was higher in macroadenomas than in microadenomas (Chi square = 11.2, P<0.01). Two women had sporadic multiple endocrine neoplasia type 1-associated syndrome. The proportion of microadenomas versus macroadenomas was 1/11 (period 1974-1986) and 8/32 (period 1987-2001). Bilateral petrosal sinus sampling, (111)In-pentreotide scintigraphy and ((11)C)-l-methionine positron emission tomography scan confirmed diagnosis in four questionable microadenomas. Macroadenomas with extrasellar extension (31 cases) had a tendency to be medially located. Medical treatment with somatostatin analogs was initiated as first-line treatment in 26 patients. TSH levels were reduced by more than 50% in 23/26 cases. A tumoral shrinkage of more than 20% was observed in 5/13 cases. Surgery was performed in 36 patients. After 1 year, 21 of them (58.3%) met the criteria of surgical favorable outcome. Pituitary radiotherapy (n=8) and somatostatin analogs allowed normalization in cases not cured by surgery. CONCLUSION: Ultrasensitive methods for TSH measurement led to an earlier recognition of TSH-secreting pituitary tumors. In this series, we observed that TSH-secreting pituitary tumors are today more frequently found at the stage of microadenomas, medially located, without associated hypersecretions and needing new exploration methods as compared with older series. This changing spectrum in the presentation of TSH-secreting pituitary tumors and the excellent response to somatostatin analogs has been accompanied by an improvement in the prognosis of the disease.
Jailer, J.W., Holub, D.A., Remission of Grave's disease following radiotherapy of a pituitary neoplasm (1960) American Journal of Medicine, 28, pp. 497-500
Grisoli, F., Leclercq, T., Winteler, J.P., Jaquet, P., Guibout, M., Diaz-Vaquez, P., Thyroid-stimulating hormone pituitary adenomas and hyperthyroidism (1986) Surgical Neurology, 25, pp. 361-368
Beckers, A., Abs, R., Mahler, C., Vandalem, J.L., Pirens, J., Hermen, G., Thyrotropin-secreting pituitary adenomas: Report of seven cases (1991) Journal of Clinical Endocrinology and Metabolism, 72, pp. 477-483
Wynne, A., Gharib, H., Scheithauer, B.W., Davis, D.H., Freeman, S.L., Horvath, E., Hyperthyroidism due to inappropriate secretion of thyrotropin in 10 patients (1992) American Journal of Medicine, 1, pp. 15-24
Mindermann, T., Wilson, C.B., Thyrotrophin-producing pituitary adenomas (1993) Journal of Neurosurgery, 79, pp. 521-527
Losa, M., Giovanelli, M., Persani, L., Mortini, P., Faglia, G., Beck-Peccoz, P., Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas (1996) Journal of Clinical Endocrinology and Metabolism, 81, pp. 3084-3090
Bertholon-Grégoire, M., Trouillas, J., Guigard, M.P., Loras, B., Tourniaire, J., Mono- and plurihormonal thyrotropic pituitary adenomas: Pathological, hormonal and clinical studies in 12 patients (1999) European Journal of Endocrinology, 140, pp. 519-527
Brucker Davis, F., Oldfield, E., Skarulis, M., Doppman, J.L., Weintraub, B.D., Thyrotropin-secreting pituitary tumours: Diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health (1999) Journal of Clinical Endocrinology and Metabolism, 84, pp. 476-486
Sanno, N., Teramoto, A., Osamura, R.Y., Long-term surgical outcome in 16 patients with thyrotropin pituitary adenoma (2000) Journal of Neurosurgery, 93, pp. 194-200
Stadnik, T., Stevenaert, A., Beckers, A., Luypaert, R., Osteaux, M., Diagnosis of primary thyrotrophin-secreting microadenoma by 1.5 T MR (1992) European Journal of Radiology, 14, pp. 124-127
Lundin, P., Pedersen, F., Volume of pituitary macroadenomas: Assessment by MRI (1992) Journal of Computer Assisted Tomography, 16, pp. 518-528
Bergstrom, M., Muhr, C., Lundberg, P.O., Langstrom, B., PET as a tool in the clinical evaluation of pituitary adenomas (1991) Journal of Nuclear Medicine, 32, pp. 610-615
Poncin, J., Stevenaert, A., Beckers, A., Somatic MEN1 gene mutation does not contribute significantly to sporadic pituitary tumorigenesis (1999) European Journal of Endocrinology, 140, pp. 573-576
Kovacs, K., Horvath, E., Tumours of the pituitary gland (1986) Atlas of Tumour Pathology, , Fascicle 21, series 2. Eds WH Harthmann & LH Sobin. Washington DC, USA: Armed Forces Institute of Pathology
Cooper, D.S., Wenig, B.M., Hyperthyroidism caused by an ectopic TSH-secreting pituitary tumor (1996) Thyroid, 6, pp. 337-343
Losa, M., Magnani, P., Mortini, P., Persani, L., Acerno, S., Giugni, E., Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: Correlation with the effect of a single administration of octreotide on serum TSH levels (1997) European Journal of Nuclear Medicine, 24, pp. 728-731
Muhr, C., Bergström, M., Lundberg, P.O., Langström, B., Positron emission tomography in the evaluation effects in pituitary adenomas (1990) Journal of Endocrinological Investigation, 13 (SUPPL. 2), pp. S79. , (Abstract)
Duet, M., Ajzenberg, C., Benelhadj, S., Lajeunie, E., Lormeau, B., Guillausseau, P.J., Somatostatin receptor scintigraphy in pituitary adenomas: A somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo (1999) Journal of Nuclear Medicine, 40, pp. 1252-1255
Asa, S.L., Puy, L.A., Lew, A.M., Sundmark, V.C., Elsholtz, H.P., Cell type-specific expression of the pituitary transcription activator pit-1 in the human pituitary and pituitary adenomas (1993) Journal of Clinical Endocrinology and Metabolism, 77, pp. 1275-1280
Safer, J.D., Colan, S.D., Fraser, L.M., Wondisford, F.E., A pituitary tumor in a patient with thyroid hormone resistance: A diagnostic dilemma (2001) Thyroid, 11, pp. 281-291
Saeki, N., Iuchi, T., Isono, S., Eda, M., Yamaura, A., Neuroradiology. MRI of growth hormone-secreting pituitary adenomas: Factors determining pretreatment hormone levels (1999) Neuroradiology, 41, pp. 765-771
Ezzat, S., Horvath, E., Kovacs, K., Smyth, H.S., Sriger, W., Asa, S.L., Basic fibroblast growth factor expression by two prolactin and thyrotropin producing pituitary adenomas (1995) Endocrinology and Pathology, 6, pp. 125-134
Chanson, P., Weintraub, B.D., Harris, A.G., Octreotide therapy for thyroid-stimulating hormones-secreting pituitary adenomas. A follow-up of 52 patients (1993) Annals of Internal Medicine, 119, pp. 236-240
Kuhn, J.M., Arlot, S., Lefebvre, H., Caron, P., Cortet-Rudelli, C., Archambaud, F., Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide (2000) Journal of Clinical Endocrinology and Metabolism, 85, pp. 1487-1491
Caron, P., Arlot, S., Bauters, C., Chanson, P., Kuhn, J.M., Pugeat, M., Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas (2001) Journal of Clinical Endocrinology and Metabolism, 86, pp. 2849-2853
Stevenaert, A., Beckers, A., Presurgical octreotide: Treatment in acromegaly (1996) Metabolism, 45 (SUPPL. 1), pp. 72-74
Reubi, J.C., Schar, J.C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J.S., Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use (2000) European Journal of Nuclear Medicine, 27, pp. 273-282
Bevan, J.S., Burke, C.W., Esiri, M.M., Adams, C.B., Ballabio, M., Faglia, G., Studies of two thyrotrophin-secreting pituitary adenomas: Evidence for dopamine deficiency (1989) Clinical Endocrinology, 31, pp. 59-70
Bétéa, D., Valdes Socin, H., Beckers, A., Pituitary pathology and MEN1 (2000) Annales D' Endocrinologie, 61, pp. 214-223
